Let's Connect

News

FDA Aligns on Key Elements of Phase 3 Study of Zervimesine for Dementia With Lewy Bodies

By Industry News 1 min read

​FDA aligns with Cognition on a phase 3 zervimesine trial for Lewy body dementia, testing 100 mg daily for 9 months to target hallucinations.  — From Psychiatric Times articles Read More

Share this post
All News posts
News Industry News 8:00 am Sleep Disruption and Alzheimer Disease: A Bidirectional, Treatable Relationship ​Sleep disruption fuels Alzheimer risk via apnea, fragmentation, and inflammation; improving consolidated sleep, medication review, and sleep-specialist teamwork may protect cognition.  — From Psychiatric Times articles Read More News Industry News 8:27 am New Multi-Arm, Multi-Stage UK Trial to Test Alzheimer Treatments ​UK AD-SMART platform trial speeds Alzheimer disease treatment discovery by testing multiple repurposed drugs at once across NHS sites, aiming to protect memory and quality of life.  — From Psychiatric Times articles Read More News Industry News 12:00 pm When Antidepressants Stop Working: Understanding Tachyphylaxis in Clinical Practice ​When an antidepressant seems to stop working, the patient’s deterioration is real. The explanation may be less certain.  — From Psychiatric Times articles Read More

Integrated Psychiatric Consultants

Office Hours:
Mon-Fri, 9 a.m. - 5 p.m. CT

Follow us

Reach out today.

Integrated Psychiatric Consultants (IPC) is committed to protecting and respecting your privacy. Our team will use the information collected here solely to serve your needs and notify you about relevant services. To consent, please check the box above and submit this form.

Please note, this consent applies to all forms of communications, including SMS. If you have provided a mobile phone number above, you agree to receiving SMS messages from IPC. You may unsubscribe at any time. Message frequency varies. Messaging and data rates may apply. Reply STOP to cancel. For more information, please review our Privacy Policy.